Immunotherapy for LELC: Case Report and a Focused Review.
Antibodies, Monoclonal
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Asian People
Carcinoma, Non-Small-Cell Lung
/ immunology
Humans
Immunotherapy
/ methods
Lung Neoplasms
/ immunology
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Respiratory Mucosa
/ pathology
Survival Analysis
Treatment Outcome
Immunotherapy
Lymphoepithelioma-like carcinoma of the lung
NSCLC
Rare tumor
Treatment
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
09
08
2017
revised:
15
10
2018
accepted:
10
12
2018
pubmed:
30
1
2019
medline:
4
4
2020
entrez:
30
1
2019
Statut:
ppublish
Résumé
Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Optimal treatment has not been clearly established. Treatment options are based on surgery for early stage and on cisplatin-based chemotherapy as first-line therapy for metastatic disease. Prognosis may seem better than for other types of non-small-cell lung cancer, but it remains poor in advanced disease, with a median survival of 24 months, and new treatments options are still warranted. Immunotherapies are now key players in the treatment of non-small-cell lung cancer. However, few data are available for this rare histologic subgroup. We have reviewed the available data on LELC with a focus on the first few cases reported with a response to a programmed cell death 1 inhibitor.
Identifiants
pubmed: 30691964
pii: S1525-7304(18)30332-2
doi: 10.1016/j.cllc.2018.12.008
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e393-e401Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.